Specific iron chelators determine the route of ferritin degradation

Area of Science:

• Biochemistry
• Cell Biology
• Pharmacology

Background:

• Deferoxamine (DFO) is an injectable iron chelator used for iron overload disorders.
• Oral iron chelators like deferiprone and desferasirox exist but have different absorption properties.
• The cellular mechanisms of iron chelation and ferritin degradation are not fully understood.

Purpose of the Study:

• To investigate the cellular mechanism by which Deferoxamine (DFO) induces ferritin degradation.
• To compare the degradation pathways of DFO with oral iron chelators (deferiprone, desferasirox).
• To elucidate the role of autophagy in DFO-mediated ferritin degradation.

Main Methods:

• Cell culture treated with Deferoxamine (DFO), deferiprone, and desferasirox.
• Analysis of LC3B protein accumulation as an indicator of autophagy.
• Inhibition of autophagy using 3-methyladenine to observe alternative degradation pathways.
• Assessment of ferritin degradation through lysosomal and proteasomal pathways.

Main Results:

• Deferoxamine (DFO) treatment induced ferritin degradation via autophagy, evidenced by cytosolic LC3B accumulation.
• Deferiprone and desferasirox treatments did not induce LC3B accumulation; ferritin degraded via the proteasome.
• Inhibition of autophagy in DFO-treated cells shifted ferritin degradation to the proteasome.
• Identified two distinct ferritin degradation routes: DFO-induced lysosomal entry and a proteasomal route.

Conclusions:

• Deferoxamine (DFO) uniquely induces ferritin degradation through an autophagy-dependent lysosomal pathway.
• Ferritin degradation can occur via distinct cellular mechanisms, influenced by the type of iron chelator used.
• Understanding these pathways may inform the development of more effective iron overload therapies.